Compare TUYA & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TUYA | MDXG |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2021 | 2007 |
| Metric | TUYA | MDXG |
|---|---|---|
| Price | $2.31 | $3.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $3.49 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.1M | 884.2K |
| Earning Date | 05-19-2026 | 04-29-2026 |
| Dividend Yield | ★ 5.19% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | $13.76 | N/A |
| Revenue Next Year | $11.90 | $13.02 |
| P/E Ratio | $27.45 | ★ $12.09 |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $1.87 | $3.77 |
| 52 Week High | $2.95 | $7.99 |
| Indicator | TUYA | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 46.28 | 26.77 |
| Support Level | $2.24 | $3.77 |
| Resistance Level | $2.46 | $7.39 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 33.33 | 14.84 |
Tuya Inc is an AI cloud platform service provider dedicated to bringing AI into everyday life. The group leverages its TuyaOpen open-source framework and universal AI Agent engines, including the AI Agent development platform, to integrate multimodal AI capabilities and reduce barriers to AI development. It drives the adoption of AI-powered lifestyles and speeds up the integration of AI with the physical world. It offers innovative physical AI solutions for smart devices, commercial use, and industry developers using cloud computing and spatial intelligence. It also provides a complete, open, and neutral global AIoT ecosystem. It builds a developer community that collaborates to create smart solutions grounded in sustainability, security, efficiency, agility, and openness.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.